NCT02157922已完成2 期
A Double-blind, Randomized, Placebo-controlled Cross Over Study of Inhaled Alginate Oligosaccharide (OligoG) Administered for 28 Days in Subjects With Cystic Fibrosis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 65
- 试验地点
- 18
- 主要终点
- FEV1 (Forced Expiratory Volume in 1 second)
研究概览
简要总结
The purpose of the study is assessment of efficacy and safety of OligoG as a dry powder formulation, in adult subjects with cystic fibrosis.
详细描述
The primary objective is to demonstrate efficacy of inhaled OligoG measured by FEV1, and supported by secondary endpoints including Mucociliary Clearance, rheology,microbiology and Quality-of-Life.
The secondary objectives are
- To demonstrate the safety and tolerability of inhaled OligoG as a dry powder for inhalation after multiple dose administration; and
- To evaluate patient compliance with treatment.
The design will be randomized, double-blind, placebo-controlled, multi-center, cross-over phase II study. Mucociliary and Cough clearance (MCC) will be an exploratory endpoint in a subset of 24 patients, and Lung Clearance Index (LCI) an exploratory endpoint in another subset of 20 or more patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female with a confirmed diagnosis of cystic fibrosis defined by:
- •Clinical features consistent with the diagnosis of CF AND Sweat chloride ≥60 mmol/L by pilocarpine iontophoresis; OR
- •Genotypic confirmation of CFTR mutation
- •Aged 18 years or older
- •Positive microbiological finding of Pseudomonas aeruginosa in expectorated sputum or cough swab within 24 months prior to Screening
- •FEV1 between 40%-100%
- •At Screening no clinical or laboratory findings suggestive of significant pulmonary illness, other than CF
- •Female subjects of child bearing potential and sexually active male subjects must use contraception
- •Provision written informed consent
排除标准
- •Changes in underlying therapy within the 14 days prior to Day
- •Subjects must be willing to remain on the same underlying stable therapy regimens for the duration of the study until the final follow-up visit.
- •Changes in physiotherapy technique or schedule within 14 days prior to Day
- •Prohibited medications within 7 days prior to Day
- •Pulmonary exacerbation within 28 days of Screening.
- •Positive microbiological finding of Burkholderia sp. in expectorated sputum or cough swab documented within 12 months prior to Screening.
- •Lactose intolerance/milk allergy.
- •On-going acute illness. Subjects must not have needed an outpatient visit, hospitalization or required any change in therapy for other pulmonary disease between Screening and Day
- •History of, or planned organ transplantation.
- •Treatment for Allergic bronchopulmonary aspergillosis (ABPA).
- •Requirement for continuous (24 hour/day) oxygen supplementation.
- •Diagnosed with the G551D-mutation, and currently on concomitant treatment with Ivacaftor (Kalydeco).
- •Concomitant administration of inhaled mannitol or hypertonic saline within 7 days prior to Day 0 (Visit 2).
- •Initiation of cycled, inhaled tobramycin (TOBI) and Colistin less than 4 months prior to Screening (Visit 1). Note: Chronic TOBI and Colistin users are allowed to participate in this study, but subjects who have recently initiated chronic TOBI or Colistin should have at least 2 cycles of TOBI or Colistin respectively in the preceding 4 months before being enrolled in this study. Treatment should be phased in line with the antibiotic treatment.
- •Concomitant use of all other marketed antibiotic agents is permitted, providing subjects are willing to remain on the same regimens within the 28 days immediately prior to Day 0 and for the entire duration of the study (until the follow-up visit).
- •Clinically significant abnormal findings on haematology or clinical chemistry. In addition, any value ≥ 3 x the upper limit of normal will exclude the subject from participating in the study.
- •Subjects unable to perform pulmonary function tests according to the ATS/ERS criteria.
- •Pregnant or breast-feeding women. A negative urine pregnancy test must be demonstrated in females of child-bearing potential (Section 4.2.9) at Screening.
- •Subjects who have participated in any interventional clinical trial within the 28 days prior to Day 0 (Visit 2).
- •Subjects with documented or suspected, clinically significant, alcohol or drug abuse.
- •Current malignant disease (with the exception of basal cell carcinoma and cervical neoplasia).
- •Any serious or active medical or psychiatric illness, which in the opinion of the Investigator, would interfere with subject treatment, assessment, or compliance with the protocol.
- •DPI intolerance, active or placebo
- •For MCC sites only:
- •Smoking. A negative Cotinine test must be demonstrated at Screening
- •Subjects who have any non-removable metal objects such as metal plates, screws etc in their head, neck, chest or abdominal area
- •Subjects for whom participation in this study will exceed the limits of total radiation exposure allowed in any 12 month period (5 mSv), or will exceed 10 mSv over any three year period.
研究组 & 干预措施
Alginate oligosaccharide
Active Comparator
Inhalation of a dry powder OligoG in the first treatment period, and of placebo the second period
干预措施: alginate oligosaccharide (Drug)
Placebo
Placebo Comparator
Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period
干预措施: alginate oligosaccharide (Drug)
结局指标
主要结局
FEV1 (Forced Expiratory Volume in 1 second)
时间窗: 28 days, i.e. start and end of treatment periods
An improvement in FEV1 during treatment with OligoG as compared to placebo is the primary endpoint of the study.
次要结局
- Mucociliary and cough clearance(28 days, i.e. start and end of treatment periods)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
2 期
A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. InfectionBurkholderia InfectionCystic FibrosisNCT02453789AlgiPharma AS15
终止
1 期
Safety, Tolerability and Pharmacokinetics of ASM-024 Administered to Healthy Subjects and Subjects With Moderate AsthmaAsthmaNCT01793298Asmacure Ltée55
已完成
2 期
Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary DiseaseNCT02948582Sunovion Respiratory Development Inc.42
已完成
不适用
Polyglucosamine L112 in Overweight and Obese SubjectsObesityNCT05022732Azienda di Servizi alla Persona di Pavia150
已完成
1 期
Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV AdministrationHypoglycemiaNCT03735225Zealand Pharma60